Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZENITH WILL MOVE INTO GENERIC INJECTABLE PRODUCT LINE

Executive Summary

ZENITH WILL MOVE INTO GENERIC INJECTABLE PRODUCT LINE in the second half of 1986, following the purchase of sterile product manufacturing facilities from Smith Labs. The agreement-in-principle was announced in May 15 press release. Details of the deal were not disclosed. "The purchase of these facilities will enable Zenith to expand significantly its pharmaceutical product line to include a line of injectable products," Zenith President and CEO James Leonard stated. "We anticipate that the purchase will be concluded in the near future and that Zenith will commence operations at the facilities during the third quarter of 1986." Wall Street reacted favorably to the acquisition; Zenith stock closed at 30-5/8 on May 15, up 2-7/8. The stock closed at 31-3/4 on May 23. Smith Labs explained its decision to sell its Rosemont, Illinois plant as a move to cut operating expenses and generate cash. In its last fiscal year, which ended Oct. 31, Smith reported a net loss of $2.1 mil. after posting earnings of $5.7 mil. the previous year. During the same period, sales dropped 36% to $14.6 mil. Smith's fiscal 1985 performance reflected a 55% decline in sales of its principal product, Chymodiactin (chymopapain for injection), which has been under competitive pressure from Baxter's Discase chymopapain product. In addition, physician concerns with the adverse reaction profile of chemonucleolysis has inhibited chymopapain sales. Smith Labs said it has at least a two-year supply of Chymodiactin. The product has a shelf life of approximately two years. The company indicated that in the future it might consider a contract production agreement with either Zenith or one of its foreign licensees.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel